News Spark divides opinion with $850,000 gene therapy Spark offers efficacy-based rebates and deferred payments to mitigate costs
News NHS should fund GSK's £526,000 "bubble baby" drug - NICE Strimvelis is most expensive drug cleared by NICE
Views & Analysis Patient involvement in HTA Considering the essential role of patient experience in HTA and the role of pharma.
News NICE to reassess Pfizer blood cancer drug Company successfully appealed against rejection last summer
Views & Analysis What is pharmaceutical market access? Findings from a comprehensive survey on the topic of market access.
Views & Analysis UK life sciences: the impact of a cycle of affordability and... The changing landscape for drug pricing and some pointers for the UK life sciences sector.
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
